HKUBio Reflects on a Successful Showcase at BIOHK2025

BIOHK2025 has officially wrapped, and what an incredible journey it’s been! We at Hong Kong Universal Biologicals Company Limited (HKUBio) were proud to stand alongside our collaborators at the Centre for Virology, Vaccinology, and Therapeutics (CVVT) to present groundbreaking innovations that are shaping the future of healthcare.

From 10–13 September, our team welcomed visitors to booth 3E-D09 at the Hong Kong Convention and Exhibition Centre (HKCEC), where we joined forces with Orimmune BioTech Limited and BiomOrgan Limited to spotlight transformative technologies in vaccines, cancer therapeutics, and organoid research.

Highlights from the Event:

• Next-Gen Influenza Vaccine Platform: HKUBio proudly showcased pioneering nasal spray vaccine based on an influenza viral vector. This platform represents a major leap forward in respiratory virus prevention, offering a needle-free, scalable solution for global immunization efforts.

  
  

• Breakthroughs in Liver Cancer Treatment: Orimmune BioTech introduced a novel antibody therapy targeting hepatocellular carcinoma (HCC). This promising innovation opens new doors for more effective and personalized cancer care.

  
  

• Advances in Respiratory Organoids: BiomOrgan Limited unveiled cutting-edge research in respiratory organoid models, offering powerful tools for disease modeling, drug screening, and precision medicine.

We’re deeply grateful to everyone who visited our booth, engaged in meaningful conversations, and shared in our vision for a healthier future. Stay tuned as HKUBio continues to push the boundaries of vaccine science and public health.